1、 For immediate release Johnson&Johnson reports Q1 2026 results,raises 2026 outloo k 202 6 First-Quarter reported sales growth of 9.9%to$24.1 Billion with operational growth of 6.4%*and adjusted operational growth of 5.3%*202 6 First-Quarter earnings per share(EPS)of$2.14 and adjusted EPS of$2.70 Com

2、pany increases 2026 guidance with estimated reported sales of$100.8 Billion or 7.0%at the midpoint,and adjusted EPS4 of$11.55 or 7.1%at the midpoint Solidifying path to double-digit growth by the end of the decade,with significant progress for patients with the approvals of ICOTYDE the first-and-onl

3、y targeted oral peptide for plaque psoriasis,TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma,VARIPULSE P ro in Europe with a new pulse sequence that is now 5 times faster,and TECNIS PureSee Intraocular Lens for U.S.Cataract Patients Compan

4、y announces planned Enterprise Business Review for December 8,2026 New Brunswick,N.J.(April 14,202 6)Johnson&Johnson(NYSE:JNJ)today announced results for first-quarter 202 6.“Johnson&Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact,”said

5、 Joaquin Duato,Chairman and Chief Executive Officer,Johnson&Johnson.“The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game-changing approvals this quarter,including ICOTYDE in the U.S.for moderate to severe plaque psoriasis a

6、nd VARIPULSE Pro in Europe.These advancements have the potential to transform patient outcomes and create sustainable,long-term value for shareholders.”Overall financial results Q1($in Millions,except EPS)2026 202 5%Change Reported Sales$24,062$21,893 9.9%Net Earnings$5,235$10,999 -52.4%EPS(diluted)